Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs WeightRx

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and WeightRx head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 271 · Grade C

WeightRx

Visit WeightRx Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 65 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make WeightRx a bad call — it's best for readers who will confirm the actual prescription, full commitment and refund deductions before selecting a long-term plan. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
48
Supply Reliability
95
74
Transparency
90
72
Access Breadth
93
50
Clinical Oversight
92
82
Track Record
88
73
CoreAge RxBrief Score 94 · 65WeightRx

Price, coverage & the tracker

CoreAge RxWeightRx
Brief Score94/100 (A)65/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Confirm full selected-plan quote

$250/month card does not establish exact formulation, complete term, initial charge or supplied quantity.

All listed plan lengths auto-renew; six- and twelve-month nonrefund rules and refund deductions need clarification.

Full price details

Semaglutide listed; exact formulation and complete selected-plan quote unknown; $250/month card lacks full term and supply conditions

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Confirm commitment behind $83/month

Lowest advertised compounded tirzepatide rate lacks complete term, first payment and supply conditions.

Cancel before renewal; nonapproval full-refund wording and five-percent processing-fee clause require clarification.

Full price details

Compounded tirzepatide offered; complete selected-plan quote unknown; $83/month advertisement lacks a complete commitment, full first payment and supplied quantity

CoverageUS only; restrictions by state, confirmed at intakeU.S. patients subject to independent clinician review; complete medication-specific state and pharmacy eligibility are not established
Brand-name accessNot confirmedFoundayo, Wegovy and Zepbound branded cards are labeled coming soon; current branded fulfillment is not established.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

WeightRx: Advertised $83 tirzepatide/$250 semaglutide monthly figures lack full selected term and supply. Long-plan nonrefund rules and refund processing deductions require confirmation.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.